FERRONATO-KGS-GROUP
24.1.2022 17:52:12 CET | Business Wire | Press release
The Swiss technology company FERRONATO KGS GROUP , which specialises in industrial metallised fabrics, forayed into the lifestyle domain with the global launch of a new smart accessories brand – FERRONATO – at the Swiss Pavilion , Expo 2020 Dubai .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005556/en/
"We have always been acknowledged for its focus on innovation tech and the new personal lifestyle accessories brand, Ferronato, is yet another milestone in our journey," said Sandro Giovanni Ferronato, CEO, FERRONATO KGS GROUP LTD.
FERRONATO KGS GROUP was established in 1906 in Lugano, Switzerland. World-renowned for its precision tools, abrasives and metallised fabrics, KGS is now helmed by a 3rd generation, led by Sandro Giovanni Ferronato.
He added, "Ferronato is a lifestyle brand borne out of a sense of immediacy that creates bespoke, high-end accessories that aim to protect your privacy.”
The Ferronato smart accessories showcased at the Swiss Pavilion include a range of personal products powered by KGS metallised fabrics, including laptop sleeves, phone pouches, totes, and briefcases that ensure the protection of privacy and personal information.
The company said the smart accessories made of metallised fabrics fit in well as an antidote to invasive surveillance threats people face at every step of their personal life.
"These smart accessories, made for our digital life, safeguard from several potential digital threats. This includes from stopping tracking of our location, remote activation of our phone to eavesdropping on our conversations to steal critical information and personal data," said Alessia Ferronato, Partner, Ferronato.
KGS said that these accessories will curb hacking, tracking, potential cybercrimes, data theft, digital infiltration and system breeches without the consent of an individual or individuals.
As the world's leading manufacturer of flexible diamond abrasives and electrolytically metallised fabrics, KGS’ industrial products are used across many industry verticals. This includes aerospace, aeronautical, defence, automotive, medical equipment, construction, telecommunications and consumer electronics.
The company, with offices in 16 countries, has been supplying products in over 100 countries from its six manufacturing sites in Switzerland, The Netherlands, Hungary, Portugal, United Arab Emirates, China and India.
For more information, please visit https://www.kgs.swiss/ and https://www.ferronato.swiss/
Instagram: https://www.instagram.com/ferronato.swiss/
Facebook: https://www.facebook.com/ferronato.swiss
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005556/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom